Evidence map›Paper›PMID 29552069›Full record

ArticleIranian journal of pharmaceutical research : IJPR2017

CDKN2B Methylation Correlates with Survival in AML Patients.

Esmat Kamali Dolatabadi, Mohammadreza Ostadali Dehaghi, Naser Amirizadeh, Kazem Parivar, Reza Mahdian

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Iranian journal of pharmaceutical research : IJPR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Esmat Kamali DolatabadiDepartment of Biology, Science and Research Branch´ Islamic Azad University, Tehran Iran.
Mohammadreza Ostadali DehaghiCell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran University of Medical Sciences.Tehran, Iran.
Naser AmirizadehIranian Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran.
Kazem ParivarDepartment of Biology, Science and Research Branch´ Islamic Azad University, Tehran Iran.
Reza MahdianMolecular Medicine Department, Pasteur Institute of Iran, Tehran, Iran.
Islamic Azad University, Science and Research Branch · IRHigh Institute for Education and Research in Transfusion Medicine · IRPasteur Institute of Iran · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aberrant DNA methylation has been reported as an important phenotype in acute myeloid leukemia. However the clinical significance of methylation changes has not been clear yet. In this study methylation Specific Melting Curve Analysis (MS-MCA) and real time PCR was used to assess the CDKN2B promoter hyper-methylation and gene expression in 59 Iranian acute myeloid leukemia (AML) patients. The incidence of aberrant hyper methylation of CDKN2B gene and cytogenetic abnormalities were 37.3% (22 of 59 patients) and 35.6% (21 of 59) respectively in our patients. We observed that CDKN2B expression level was lower than normal mesenchymal stem cells. Our data revealed significant correlation between methylated

Indexed as

AMLEpigeneticMelting curve analysis (MCA)MethylationReal-Time PCR

Identifiers

PMID29552069
PMCPMC5843322
OpenAlexW2751769043

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.